ClinicalTrials.gg
CompletedNCT04262284AmAREtTIUpdated May 28, 2025

Respreeza® Self-administration and Learning Program (AmAREtTI Study)

An observational study in Alpha-1 Antitrypsin Deficiency, sponsored by CSL Behring. Completed at 11 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-28.

Sponsored by CSL Behring (part of CSL Limited) · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
15
Ages
18 Years and older
Sex
All
01

Study summary

According to the Respreeza® Summary of Product Characteristics, the initial infusions must be administered under the supervision of a health professional experienced in the treatment of alpha-1 antitrypsin deficiency, although subsequent infusions may be administered at home by the person responsible for care or by the patient.

Clinical data on self-administration of Respreeza® are however limited and the grounds for self-administration are left to the assessment of the attending physician, who needs to ensure that appropriate training is delivered.

In this context, CSL Behring would like to run a clinical study in order to assess the effectiveness of a home self-administration learning program in terms of switching to self-administration, and the long term maintenance of this administration.

02

Conditions studied

  • Alpha-1 Antitrypsin Deficiency
03

In context

alpha 1-Antitrypsin Deficiency

142 studies on the registry are indexed under alpha 1-Antitrypsin Deficiency; 32 are open to participants now.

This study's enrollment of 15 is below the median of 160 across 46 observational studies indexed under alpha 1-Antitrypsin Deficiency.

Browse alpha 1-Antitrypsin Deficiency studies →

Lead sponsor

CSL Behring is the lead sponsor of 145 studies on the registry; 17 are open to participants now.

Of its 24 completed or terminated interventional studies of FDA-regulated products, 17 (71%) have results posted.

First submitted after CSL Behring became part of CSL Limited.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients suffering from alpha-1 antitrypsin deficiency (AATD) treated by Respreeza®

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients (age ≥18 years old).
  • Patients suffering from AATD treated by Respreeza® through a peripheral vein at home for at least 3 month (consecutives or not). The 3-month period of treatment with Respreeza® does not necessarily correspond to the 3 months prior to inclusion.
  • Patient accompanied by a third person at home
  • Patients deemed to be suitable by the investigator for self-administration.
  • Patients with a of over 3 years.
  • Patients who have been informed verbally and in writing via the information leaflet and who have signed the form.

Exclusion criteria

Exclusion Criteria:

  • In order to reflect the reality of everyday practice, no non-inclusion criteria are intended except for patient refusal to take part in the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
15 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Percentage of patients who switch to self-administration without the presence of a nurse at the end of the learning program

    A patient will be permitted to switch to self-administration without the presence of a nurse if the following conditions are met: * Three consecutive successful self-administrations by the patient in the presence of the nurse but without assistance during the learning phase. * Validation of the learning grid The percentage is based on number of patient switching to self-administration and remains in self-administration 12 months after

    Time frame: Up to 8 weeks

  2. Percentage of patients who switch to self-administration without the presence of a nurse

    Time frame: Up to 12 months

Secondary outcomes

  1. Percentage of patients who switch to self-administration without the presence of a nurse

    A patient will be permitted to switch to self-administration without the presence of a nurse if the following conditions are met: * Three consecutive successful self-administrations by the patient in the presence of the nurse but without assistance during the learning phase. * Validation of the learning grid The percentage is based on number of patient switching to self-administration

    Time frame: Up to 8 weeks

  2. Patient characteristics

    Socio-demographic data, disease history, concomitant treatments, substitution protocol, percentage of theoretical forced expiratory volume at one second (FEV1), diffusing capacity of lung for carbon monoxide (DLCO), distance from home to hospital, type of follow-up (in hospital, in surgery)

    Time frame: At inclusion

  3. Degree of autonomy

    The change in the degree of autonomy will be defined as the difference between the autonomy assessed at 12 months and inclusion according to an EVA

    Time frame: At inclusion and 12 months after self-administration

  4. The time frame for autonomy

    The time to achieve autonomy will be defined by the time between the first learning session for self-administration and the first self-administration without nurse.

    Time frame: Up to 12 months

  5. Evolution of patients Quality of Life with Saint George's Respiratory Questionnaire (SGRQ)

    Time frame: Up to 12 months

  6. Patients satisfaction for treatment administration by a nurse and for self-administration

    Satisfaction for treatment administration by a nurse will be assessed at inclusion by visual analog scale (VAS) Satisfaction for self-administration will be assessed after 12 months after the 1st self-administration or in case of study withdrawal by VAS

    Time frame: Up to 12 months

  7. Satisfaction about learning program

    Satisfaction about learning program will be assessed at the end of the learning program by VAS

    Time frame: Up to 8 weeks

  8. Tolerance and safety

    General and local tolerance at the administration site assessed by the nature and number of adverse events (AEs) and immunoglobulin E impaired gas exchange (IGEs).

    Time frame: Up to 12 months

  9. Compliance/Observance

    Compliance/observance measured by the number of scheduled and unrealized sessions.

    Time frame: Up to 8 weeks

  10. Determining factors for switch to self-administration

    Determining factors that may be associated with the transition to self-administration (demographics, disease history, concomitant treatments, substitution protocol, FEV1, QoL at inclusion, duration of learning program).

    Time frame: Up to 8 weeks

07

Study locations

11 sites
  • CHU Angers
    Angers, France
  • CHU Bordeaux - Hôpital Haut-Lévèque
    Bordeaux, France
  • CHU Grenoble-Alpes
    Grenoble, France
  • CHU Lille
    Lille, France
  • Hospices Civils de Lyon
    Lyon, France
  • Hôpital Saint Joseph
    Marseille, France
  • Hôpital Bichat-Claude-Bernard
    Paris, France
  • CHU Rennes - Hôpital Pontchaillou
    Rennes, France
  • CHU Strasbourg
    Strasbourg, France
  • CHRU Tours
    Tours, France
  • CHU Nancy Brabois
    Vandœuvre-lès-Nancy, France
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2019 to primary completion in May 2024, 54 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2020
First posted
Feb 10, 2020
StartActual
Oct 18, 2019
Primary completionActual
May 6, 2024
CompletionActual
May 6, 2024
Last update
May 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04262284
Lead sponsor
CSL Behring
Responsible party
Sponsor
First posted
Feb 10, 2020
Start date
Oct 18, 2019
Primary completion
May 6, 2024
Completion
May 6, 2024
Last update
May 28, 2025

Study contacts

Study Physician
study director · CSL Behring SA

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion